| 000 | 01566 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513170351.0 | ||
| 264 | 0 | _c19990604 | |
| 008 | 199906s 0 0 eng d | ||
| 022 | _a0340-6245 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBurke, S E | |
| 245 | 0 | 0 |
_aProfile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model. _h[electronic resource] |
| 260 |
_bThrombosis and haemostasis _cFeb 1999 |
||
| 300 |
_a301-5 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aArterial Occlusive Diseases _xdrug therapy |
| 650 | 0 | 4 | _aDogs |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aFemoral Artery |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aHindlimb _xblood supply |
| 650 | 0 | 4 | _aInfusions, Intra-Arterial |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadministration & dosage |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 |
_aRegional Blood Flow _xdrug effects |
| 650 | 0 | 4 | _aThrombolytic Therapy |
| 650 | 0 | 4 |
_aThrombosis _xdrug therapy |
| 650 | 0 | 4 |
_aUrokinase-Type Plasminogen Activator _xadministration & dosage |
| 700 | 1 | _aLubbers, N L | |
| 700 | 1 | _aNelson, R A | |
| 700 | 1 | _aWegner, C D | |
| 700 | 1 | _aCox, B F | |
| 773 | 0 |
_tThrombosis and haemostasis _gvol. 81 _gno. 2 _gp. 301-5 |
|
| 999 |
_c10024262 _d10024262 |
||